Abstract
ATP-sensitive potassium channels (KATP channels) of pancreatic β-cells play key roles in glucose-stimulated insulin secretion by linking metabolic signals to cell excitability. Membrane phosphoinositides, in particular phosphatidylinositol 4,5-bisphosphates (PIP2), stimulate KATP channels and decrease channel sensitivity to ATP inhibition; as such, they have been postulated as critical regulators of KATP channels and hence of insulin secretion in β-cells. Here, we tested this hypothesis by manipulating the interactions between KATP channels and membrane phospholipids in a β-cell line, INS-1, and assessing how the manipulations affect membrane excitability and insulin secretion. We demonstrate that disruption of channel interactions with PIP2 by overexpressing PIP2-insensitive channel subunits leads to membrane depolarization and elevated basal level insulin secretion at low glucose concentrations. By contrast, facilitation of channel interactions with PIP2 by upregulating PIP2 levels via overexpression of a lipid kinase, PI-4-phosphate 5 kinase, decreases the ATP-sensitivity of endogenous KATP channels by ∼26-fold and renders INS-1 cells hyperpolarized, unable to secrete insulin properly in the face of high glucose. Our results establish an important role of the interaction between membrane phosphoinositides and KATP channels in regulating insulin secretion.
Keywords: KATP, PIP2, insulin secretion, Kir6.2, INS-1 cells
INTRODUCTION
Pancreatic β-cells secrete insulin in response to glucose stimulus. The ATP-sensitive potassium (KATP) channel, a complex of four inwardly rectifying potassium channel Kir6.2 subunits and four sulfonylurea receptor 1 (SUR1) subunits, is a key component in this stimulus-secretion coupling process (1-3). The hallmark features of KATP channels are their sensitivities to intracellular nucleotides ATP and ADP, the derivatives of glucose metabolism (1; 2). ATP inhibits channel activity whereas ADP, in complex with Mg2+, stimulates channel activity. It is now generally accepted that the physiological activity of KATP channels is regulated primarily by the relative concentrations of ATP and ADP (1; 4; 5). As plasma glucose rises, the ATP concentration increases and ADP concentration decreases, resulting in KATP channel closure, membrane depolarization, Ca2+ influx and insulin release. Conversely, when glucose falls, the concentration ratio of ATP to ADP decreases, leading to KATP channel opening, membrane hyperpolarization, and termination of insulin secretion. The importance of ATP and ADP in regulating KATP channels in vivo has been confirmed by the finding that mutations which reduce channel sensitivity to ATP or MgADP are causative in permanent neonatal diabetes or congenital hyperinsulinism, respectively (5-9).
The discovery that membrane phosphoinositides, in particular the most abundant phosphoinositide phosphatidylinositol 4,5-bisphosphate (PIP2) (10), stimulate KATP channel activity and antagonize the inhibitory effect of ATP in isolated membrane patches (11; 12), has led to the proposal that in addition to ATP and ADP, PIP2 may also be important in controlling the physiological activity of KATP channels in β-cells (11-14). However, to date, direct evidence for a role of membrane phosphoinositides in regulating KATP channel activity, hence regulation of insulin secretion, in β-cells is still lacking (15).
In addition to modulating the activity of transporters and ion channels, phosphoinositides play significant roles in membrane trafficking and cytoskeleton organization (16; 17). Recent studies show that adequate PIP2 levels are necessary for cytoskeleton rearrangement and priming of insulin secretory granules (18; 19). These studies highlight the complex role of phosphoinositides in insulin secretion and the need to elucidate the physiological relevance of KATP channel gating by PIP2 in the context of β-cell function and insulin secretion. In this work, we manipulated the interactions between KATP channels and membrane PIP2 in insulin-secreting cells and examined the effects of such manipulations on KATP channel activity and insulin secretion. We show that disrupting the interaction between KATP channels and PIP2 by overexpressing Kir6.2 mutants with decreased sensitivity to PIP2 causes persistent membrane depolarization and elevated basal level insulin secretion. On the other hand, promoting channel-PIP2 interactions by expressing a murine type Iβ PI-4-phosphate 5 kinase (PIP5K) (20; 21), which increases PIP2 levels, thereby KATP channel activity, renders INS-1 cells less able to couple glucose stimulation to insulin secretion. The results provide direct evidence that regulation of KATP channel activity by phosphoinositides plays an integral role in insulin secretion.
RESEARCH DESIGN AND METHODS
Molecular biology. Kir6.2 containing point mutations or the HA-epitope tag (-YPYDVPDYA-inserted between amino acid 100 and 101 of Kir6.2; an extra 9 amino acids, -DLYAYMEKG-, was inserted between amino acid 98 and 99 to aid accessibility of the epitope) were prepared using the QuickChange site-directed mutagenesis kit (Stratagene) and subcloned into the pCMV6b vector. Recombinant adenoviruses were constructed using the AdEasy system (Stratagene). The cDNAs encoding wild-type PIP5K Iβ (PIP5K:WT) or a deletion mutant lacking the N-terminal 238 amino acids (PIP5K: Δ1-238) (20), or the various rat Kir6.2 WT and mutants were subcloned into the pCMV shuttle vector (pShuttle). They were then recombined with the pAdEasy vector in the BJ5183 strain of E. Coli. Positive recombinants were selected and pAdEasy plasmids containing the correct insert were used to transfect HEK293 cells for virus production. Single plaques were isolated for further amplification in HEK293 cells. Recombinant viruses were purified on a CsCl gradient and titers determined by spectrometry. All constructs were sequenced to verify the correct mutations.
Infection of INS-1 cells with adenovirus. For protein expression in INS-1 cells, recombinant adenoviruses with desired titers were used for infection as follows. INS-1 cells [clone 832/13, a gift from Dr. Chris Newgard (22)] were plated at 106 cells/35mm dish and cultured in RPMI-1640 with 11.1 mM D-glucose (Invitrogen) supplemented with 10% FBS, 100U/ml penicillin, 100μg/ml streptomycin, 10 mM HEPES, 2 mM glutamine, 1 mM sodium pyruvate, and 50 μM β-mercaptoethanol. Twenty-four hours later, cells were infected with appropriate titer of each adenovirus diluted in 1 ml of OptiMEM at 37°C for 1.5 hours. One ml of RPMI-1640 with 2x supplement was then added to each dish for overnight incubation. The next day, the infection medium was replaced with regular medium and incubated for another day before the experiment.
Immunoblotting and immunostaining. INS-1 cells were lysed 24 hours post-infection in 20 mM HEPES, pH 7.0/5 mM EDTA/150 mM NaCl/1% Nonidet P-40 (IGAPEL) with CompleteTR protease inhibitors (Roche Applied Science, Indianapolis, IN). Proteins were separated by SDS/PAGE, transferred to nitrocellulose membrane, and probed with appropriate primary antibodies followed by horseradish peroxidase (HRP)-conjugated secondary antibodies (Amersham Biosciences, Piscataway, NJ), and visualized by enhanced chemiluminescence (Super Signal West Femto; Pierce, Rockford, IL). The primary antibodies used are: rabbit polyclonal anti-Kir6.2 for Kir6.2 (Santa Cruz Biotechnology, Santa Cruz, CA) and rabbit polyclonal anti-PIP5K (which recognizes both the WT and the Δ1-238 mutant, kindly provided by Dr. J. Nathan Davis) for PIP5K:WT and PIP5K: Δ1-238. To confirm expression of mutant Kir6.2 at the cell surface, living INS-1 cells infected with a virus carrying HA-tagged R206A Kir6.2 were immunostained for surface HA using protocols described previously (23).
Phospholipids assays. INS-1 cells were grown on 35 mm dishes and infected with PIP5K:WT or PIP5K:Δ1-238 viruses. Twenty-four hours post-infection, cells were preincubated for 1 hour in a phosphate-free medium prior to labeling with 20 μCi of 32P for 4 hours. Cells were then washed twice with phosphate-free medium and scraped into 1ml of MeOH: HCl (10:1). After scraping, the dish was washed again with 1ml of 2mM AlCl3 in H2O, and the wash was combined with the cell lysate. The lipids were extracted by 2ml of CHCl3. The aqueous phase was transferred to a new tube and extraction repeated twice. The CHCl3 phase from the three extractions was combined, and extracted with 2ml of MeOH: HCl (1:1). The final lipid extract was dried and resuspended in 15 μl of solvent (CHCl3:MeOH:10mM HCl= 20:10:1), and analyzed by thin layer chromatography using oxalate-coated plate. About 30 μg of each lipid standard in the same solvent was run simultaneously. The plates were developed with CHCl3:MeOH: H2O:NH4OH (90:90:20:7), and the labeled phospholipids quantified by phosphorimaging. Lipid standards were visualized by iodine staining.
Electrophysiology. Resting membrane potential (RMP) of INS-1 cells was measured at room temperature using whole-cell or perforated patch-clamp recording with the Axopatch 1D amplifier and Clampex 8.1 (Axon Inc., Foster City, CA). For measuring the RMP in 3 or 12 mM glucose, cells were pre-incubated in indicated glucose concentrations for three hours prior to recording. During recording, cells were bathed in Tyrode's solution consisting of (in mM): 137 NaCl, 5.4 KCl, 1.8 CaCl2, 0.5 MgCl2, 5 HEPES, 3 NaHCO3, 0.16 NaH2PO4, with glucose as specified in figure legends. Pipette solution contained (in mM) 140 KCl, 10 HEPES, 1 EGTA, and 1 EDTA (referred to as K-INT) and 1 ATP plus 1 MgCl2 for experiments shown in Figure 1. For measuring RMP at 12 mM glucose using whole-cell patch-clamp recording, pipette solution contained 10 KCl, 130 Kgluconate, 10 HEPES, 1 EGTA, 3 MgCl2, and 5 ATP. The pH of all solutions was adjusted to ∼7.2. To measure RMP without dialyzing internal cellular contents, the perforated patch was adopted. The pipette resistance ranged between 3-5 MΩ. The tip solution was first filled up to ∼0.5 mm with the clean pipette solution containing (in mM): 76 K2SO4, 10 NaCl, 10 KCl, 1MgCl2, 5 HEPES, pH∼7.2, the pipette was then backfilled with the pipette solution containing 160∼250 μg/ml amphotericin B (Sigma). The stable perforated patch usually followed after 6-10 minutes of initial Giga seal. For ATP-sensitivity measurement, inside-out patch-clamp recording was employed as described previously (21). K-INT was used in both the bath and pipette solution. All currents were measured at a membrane potential of -50 mV (pipette voltage = +50 mV). ATP-dose response curves were fitted by the Hill equation: Irel = 1/{1+([ATP]/Ki)H}. All data are presented as mean ± standard error of the mean (s.e.m.).
FIG. 1.

Effects of PIP2-insensitive mutants on INS-1 cell membrane potential. (A) INS-1 cell membrane potential was monitored by whole-cell recordings in current clamp mode. Cells were bathed in Tyrode's solution with 3 mM glucose. The pipette solution contained 1 mM ATP and 1 mM MgCl2. Shown are representative recordings from uninfected cells or cells infected with WT, R176A, or the R206A-Kir6.2 virus. While the resting membrane potential of an uninfected cell or a cell infected with WT Kir6.2 virus hyperpolarized to a steady value of ∼ -70mV soon after break-in (due to perfusion with 1 mM MgATP which is likely lower than the intracellular MgATP concentration before break-in), that of a cell infected with the R176A, or R206A-Kir6.2 virus was much more depolarized (∼ -40 mV) and remained depolarized even after perfusion with pipette solution containing 1 mM ATP. The depolarized membrane potential could be hyperpolarized to the level close to that seen in uninfected cells by adding 250 μM of the KATP channel opener diazoxide to the bath solution. (B) Averaged steady state resting membrane potential using whole-cell patch clamp recording shown in A (n = 18 -39). (C) Averaged membrane potential measured by perforated patch-clamp recording in uninfected cells or cells infected with the WT or the R177A mutant Kir6.2 virus at 3 mM glucose (n = 8 -13). In both B and C, the error bar is the s.e.m. *p < 0.001 using Student's t test for paired data (the same statistical analysis was used in all subsequent figures).
Membrane capacitance measurements were carried out in the standard whole-cell configuration, using an EPC-9 amplifier and Pulse software (version 8.4; Heka Elektronik, Lambrecht, Germany). Patch electrodes were made from borosilicate glass capillaries, coated with dental wax (Kerr Corp, Romulus, MI) at the tips and fire-polished. The cells were constantly perfused with pre-warmed extracellular solution consisting of (in mM) 138 NaCl, 5.6 KCl, 1.2 MgCl2, 2.6 CaCl2, and 5 HEPES (pH 7.4 with NaOH). The pipette solution contained (in mM) 125 CsMeSO, 25 CsCl, 10 NaCl, 1 MgCl2, 10 HEPES, 0.05 EGTA, 3 Mg ATP, 0.01 GTP, pH 7.2. The temperature close to the cell was 32-34°C. Exocytosis was elicited by a train of six (at 1 Hz) 300 ms voltage-clamp depolarization from -70 mV to zero, and detected as changes in cell capacitance estimated by the Lindau-Neher technique (“Sine + DC”-feature of the lock-in software module). The amplitude of the sine wave was 20 mV and the frequency set as 500 Hz.
Insulin secretion assay. INS-1 cells were seeded in 24-well tissue culture plates at ∼5 x 105 /well, cultured for ∼24 hours, and infected with viruses as described above. Twenty-four hours post-infection, the culture medium was replaced by RPMI 1640 with 5 mM glucose and cells incubated for at least 18 hours. Insulin secretion was assayed in HEPES balanced salt solution (HBSS) consisting of (in mM) 114 NaCl, 4.7 KCl, 1 MgCl2, 1.2 KH2PO4, 1.16 MgSO4, 20 HEPES, 2.5 CaCl2, 25.5 NaHCO3, and 0.2% bovine serum albumin (pH ∼ 7.2) (22). Cells were washed twice with pre-warmed (37°C) HBSS buffer with 3 mM glucose followed by 2-hour incubation in the same buffer prior to stimulation with 0.8 ml/well pre-warmed HBSS buffer containing 3 or 12 mM glucose for 2 hours. The medium was harvested and insulin content determined using Immunochem coated-tube insulin radioimmunoassay (RIA) from ICN Pharmaceuticals (Costa Mesa, CA). Insulin release in different concentrations of glucose was normalized to that observed at 3 mM glucose and expressed as fold-increase.
RESULTS
Disruption of KATP channel-PIP2 interactions in INS-1 cells results in depolarized membrane potential and increased basal level insulin secretion. PIP2 exerts its effect on KATP channel gating largely via the Kir6.2 subunit (11; 12). There is evidence that binding of the negatively charged phosphate groups of membrane PIP2 to the cytoplasmic domain of Kir6.2 leads to channel opening (11; 12; 24-27). Several positively charged Kir6.2 residues critical for channel gating by PIP2 have been identified, including R176, R177, and R206 (11; 12; 27). Mutation of these residues to the neutral amino acid alanine either reduces or abolishes channel activity in inside-out membrane patches in the absence of inhibitory ATP (these mutants are referred to as PIP2-insensitive mutants hereinafter). To elucidate the role of KATP channel-PIP2 interactions in β-cell excitability and insulin secretion, we sought to disrupt channel-PIP2 interactions by overexpressing PIP2-insensitive Kir6.2 mutants in the rat β-cell line INS-1 clone 832/13, which exhibits robust insulin response to glucose stimulation (22). In COS cells, coexpression of the PIP2-insensitive Kir6.2 mutant with WT Kir6.2 at 1:1 molar ratio in the presence of SUR1 led to > 50% reduction in total KATP currents (data not shown). Mutant Kir6.2 expressed in INS-1 cells is therefore expected to compete with endogenous WT Kir6.2 for incorporation into the channel complex and reduces overall channel sensitivity to PIP2. Reduced KATP channel activity is in turn expected to cause membrane depolarization even in the absence of glucose stimulation (28). We have chosen the recombinant adenovirus approach for expressing mutant Kir6.2 in INS-1 cells since it is much more efficient than conventional transfection methods (29); infection with adenoviruses carrying the green fluorescence protein (GFP) gene yielded > 95% GFP-positive cells 12 hours after infection.
As shown in Figure 1, in cells expressing the R176A, R177A, or the R206A Kir6.2 mutant, the resting membrane potential (as assessed by whole-cell patch-clamp recording with pipette solution containing 1 mM ATP and 1 mM MgCl2) in low glucose (3 mM) was indeed significantly more depolarized (∼ -35-40 mV) than that observed in uninfected control cells (∼ -72 mV) or cells expressing either GFP (∼ -74 mV) or WT Kir6.2 (∼ -69 mV). To further validate the membrane potential obtained using whole-cell patch-clamp recording, we also measured membrane potential using perforated patch-clamp recording, a procedure that better preserves the intracellular milieu. A substantially more depolarized membrane potential was again observed in cells infected with the PIP2-insenstive R177A Kir6.2 mutant compared with uninfected cells or cells infected with WT Kir6.2 at low (3 mM) glucose (Fig.1C), but not at high (12 mM) glucose (not shown). Note the membrane potential obtained using the perforated patch-clamp technique was about 20 mV more depolarized than that obtained by whole-cell recording after dialysis with 1 mM MgATP. The difference likely reflects the higher intracellular MgATP concentration in intact INS-1 cells. The above results are consistent with the notion that KATP channel-membrane PIP2 interactions are necessary to sustain KATP channel activity and maintain the membrane potential at the resting hyperpolarized state in the absence of glucose stimulation. The depolarized membrane potential in cells expressing mutant Kir6.2 could largely be hyperpolarized to the level seen in uninfected cells (R206A is shown as an example) by adding the KATP channel opener diazoxide in the bath solution, demonstrating that the depolarized membrane potential is not due to adverse effects of virus infection or mutant Kir6.2 expression on the health of the cell. Although PIP2-insenstive Kir6.2 mutants have been reported to render the channel less responsive to diazoxide (30; 31), residual sensitivity of mutant channels to the channel opener as well as endogenous WT Kir6.2 subunits present in some channels may be sufficient to confer the diazoxide sensitivity we observed.
To ensure that the titer of each recombinant Kir6.2 adenovirus used for infection gives rise to similar protein expression level, we analyzed Kir6.2 protein level by immunoblotting. Furthermore, to confirm that the mutant Kir6.2 subunit is incorporated into the channel complex and expressed on the surface of INS-1 cells, we tagged one of the mutant, R206A, with a HA-epitope tag in the extracellular domain between amino acid 100 and 101 (HA-R206A-Kir6.2). This extracellular epitope tag allows for evaluation of surface expression of the mutant without permeabilizing the cell; the HA-tag does not interfere with the function of the channel (data not shown). As Fig.2A illustrates, the titer of each of the WT-, R176A-, R177A-, or HA-R206A-Kir6.2 viruses could be adjusted to obtain similar protein expression levels (∼5-fold of endogenous Kir6.2). Immunofluorescent staining of HA-R206A-Kir6.2 also confirmed that the mutant protein is indeed incorporated into the channel complex and expressed at the cell surface (Fig.2B).
FIG. 2.

Overexpression of PIP2-insensitive mutants causes depolarized membrane potential and elevated insulin secretion at basal glucose. (A) Western blots of endogenous and exogenous Kir6.2 or HA-R206A-Kir6.2 (which has slightly higher molecular mass) expressed in INS-1 cells using anti-Kir6.2 antibodies. Note at the virus titer used for experiments shown in this study, the exogenous Kir6.2 protein is in ∼5-fold excess (as assessed by densitometry) to endogenous Kir6.2 detected in uninfected cells. Molecular mass markers for all three blots are the same, as shown on the left. (B) Surface staining of HA-tagged R206A-Kir6.2 using an anti-HA antibody verifies that the mutant Kir6.2 is incorporated into the channel complex and expressed on the cell surface. Staining of uninfected cells using the same antibody did not give rise to detectable fluorescent signal (not shown). (C) Averaged membrane capacitance changes in response to voltage-clamp depolarization from -70 mV to 0 mV in control cells (infected with a GFP virus) and cells infected with the HA-R206A-Kir6.2 virus. There is no statistically significant difference between the two groups. (D) Insulin secretion in response to 3 mM or 12 mM glucose stimulation. The response is normalized to that observed in uninfected cells at 3 mM glucose. Cells infected with the R176A, R177A, or HA-R206A virus showed significantly(*p < 0.001) elevated insulin secretion response at 3 mM glucose (1.9 ± 0.1, 2.4 ± 0.1, 3.6 ± 0.4 folds, respectively, n = 5-9) compare with cells infected with the WT Kir6.2 virus (1.1 ± 0.1). By contrast, no significant difference was observed at 12 mM glucose. (E) Opening of KATP channels by diazoxide (250 μM) consistently reversed the effect of all three PIP2-insensitive Kir6.2 mutants on basal insulin secretion, although the extent of reversal varied.
Next, we evaluated insulin secretion response in cells expressing the various PIP2-insensitive Kir6.2 mutants at both low (3 mM) and high (12 mM) glucose concentrations. These glucose concentrations represent basal and maximal insulin response to glucose stimulation, respectively, based on a glucose dose response curve (0 - 20 mM glucose) established in INS-1 cells (not shown) (22). To exclude a direct effect of the Kir6.2 mutant on the insulin secretory machinery, we first measured membrane capacitance changes in response to 500 ms voltage-clamp depolarization. In these experiments, effects of channel-PIP2 interactions on the membrane potential are excluded and the capacitance change represents fusion of insulin granules that are available for immediate release upon the evoked membrane depolarization. Figure 2C shows that no significant difference in capacitance increase is detected between GFP virus infected control cells and cells expressing HA-R206A-Kir6.2. Insulin secretion assays demonstrated that at 3 mM glucose, while cells infected with WT-Kir6.2 virus had insulin secretion response indistinguishable from that observed in uninfected control cells (1.1-fold), cells infected with each of the three PIP2-insensitive Kir6.2 mutants all exhibited significantly elevated insulin secretion (1.9-, 2.4-, and 3.6-fold that of uninfected cells for R176A, R177A, and HA-R206A, respectively; Fig.2D). These results are consistent with the electrophysiological data (Fig.1) showing depolarized membrane potential in cells expressing the PIP2-insensitive mutants. As expected, at high glucose concentration (12 mM) no significant difference in insulin secretion response could be discerned between cells expressing the various Kir6.2 or uninfected cells since the membrane depolarizing effect caused by the mutant Kir6.2 is now masked by the depolarizing effect caused by high glucose stimulation. Also consistent with the electrophysiological data, treatment of cells with diazoxide reversed the elevated basal level insulin secretion in cells expressing the PIP2-insensitive Kir6.2 mutants to varying extents (Fig.2E). The results described above provide strong evidence that KATP channel-PIP2 interactions are necessary to allow channel opening and to prevent insulin secretion when glucose concentration is low.
Enhancing KATP channel-PIP2 interactions reduces channel sensitivity to ATP inhibition, and attenuates membrane depolarization and insulin secretion upon glucose stimulation. To assess how increased interactions between KATP channels and PIP2 affect β-cell excitability and insulin secretion, we sought to upregulate PIP2 levels by overexpressing a lipid kinase, PI-4-phosphate 5-kinase (murine type I isoform β; referred to as PIP5K:WT), which is involved in the synthesis of PI-4,5-P2 (10; 20; 21). Overexpression of PIP5K:WT in COSm6 cells has previously been shown to decrease the ATP sensitivity of KATP channels exogenously expressed in those cells (21). As a negative control, we infected cells with viruses carrying a mutant kinase whose N-terminal 238 amino acids have been deleted to remove its enzymatic activity (referred to as PIP5K:Δ1-238) (20; 21). Fig.3A is a Western blot showing similar expression level of PI4P5K:WT or PIP5K:Δ1-238 in INS-1 cells. To validate that expression of PIP5K:WT increases PIP2 levels, we metabolically labeled cells with 32P and analyzed the 32P-labeled phospholipids by thin layer chromatography (Fig.3B). The amount of PIP2 in cells expressing PIP5K:WT was dramatically increased (∼30-fold) compared with uninfected cells or cells expressing PIP5K:Δ1-238.
FIG. 3.

Infection of INS-1 cells with the PIP5K:WT virus increases cellular PIP2 level. (A) Western blots of the WT PI4P-5 kinase (PIP5K:WT) and the N-terminal deletion mutant kinase (PIP5K:Δ1-238). Titers of the two viruses used to infect cells were adjusted to achieve similar protein expression levels in this the subsequent two figures. (B) PIP2 measured in uninfected cells, cells infected with the PIP5K:WT virus, or the PIP5K:Δ1-238 virus. Standards of PA (phosphatidic acid), PI-4-P, and PI-4,5-P2 were run on the same silica gel and visualized by iodine spray to help identify the different phospholipid species. 32P-labeled PIP2 was quantified using a PhosphorImager.
We next examined how the increased PIP2 affects KATP channel activity by inside-out patch-clamp recording. In these experiments, patches were excised into K-INT solution with no ATP and then exposed quickly to K-INT containing various concentrations of ATP (all in the absence of Mg2+) before any significant current rundown occurred to ensure accurate measurement of ATP dose response (Fig.4A) (21). As shown in Fig.4B, KATP channels in cells infected with the PIP5K:WT virus exhibited a ∼26-fold decrease in ATP sensitivity compared with channels in uninfected cells or cells infected with the PIP5K:Δ1-238 virus. The large rightward shift in ATP dose response is predicted to cause KATP channels to remain active even when the glucose level rises, resulting in hyperpolarized membrane potential and reduced insulin response. To test these, we examined the membrane potential at high glucose using perforated patch-clamp technique. As mentioned above, the perforated-patch recording permits measurement of membrane potential without disturbing intracellular factors that are involved in regulating KATP channel activity. Indeed, we found at 12 mM glucose the averaged membrane potential is significantly more hyperpolarized in cells infected with the PIP5K:WT virus than in uninfected cells or cells infected with the PIP5K:Δ1-238 virus (Fig.4C). Similar results were obtained using whole-cell recordings with 12 mM glucose in the bath solution and 5mM ATP plus 3 mM Mg2+ in the pipette solution (not shown). Accordingly, while in uninfected cells or cells infected with the PIP5K:Δ1-238 virus increasing the glucose concentration from 3 to 12 mM led to a 9.5- and 8.4-fold increase in insulin release, respectively, in cells infected with the PIP5K:WT virus, the same glucose concentration change only caused a 3.5-fold increase in insulin release (Fig.5A). This reduced secretion is not due to inability of insulin granules to fuse with the membrane, since no difference in membrane capacitance increase was found between cells infected with the PIP5K:WT virus and uninfected cells, either during the first depolarization or during an entire train of step voltage-clamp depolarizations (Fig.5C). In addition, overexpression of PIP5K did not alter voltage-gated Ca2+-currents during these experiments (shown as the charge influx in Fig. 5D) (32). These results lead us to conclude that overexpression of PIP2 reduces insulin secretion at high glucose by rendering KATP channels insensitive to ATP.
FIG. 4.

Overexpression of PIP5K:WT reduces KATP channel sensitivity to ATP, and causes membrane hyperpolarization and attenuated insulin secretion at high glucose. (A) Representative inside-out patch clamp recordings of KATP currents from control INS-1 cells or cells overexpressing PIP5K:WT or PIP5K:Δ1-238. Patches were exposed to different concentrations of ATP as indicated by the bars above the recording. Experiments were done in symmetrical K-INT solution at -50 mV. Inward currents were shown as upward deflections. (B) ATP dose response curves derived from recordings shown in A. The curves were fit by the Hill equation (Irel = 1/(1+([ATP]/K1/2)H); Irel = current in [ATP]/current in zero ATP; H = Hill coefficient; K1/2 = [ATP] causing half-maximal inhibition) to averaged data. Channels of uninfected cells exhibit an expected K1/2 of 8.4 μM (H = 1.04). By contrast, channels of cells overexpressing PIP5K:WT have a K1/2 of 260.7 μM (H = 1.4), ∼26-fold higher than channels of uninfected cells or cells infected with PIP5K:Δ1-238 (K1/2 of 11.3 μM, H = 1.4). (C) Averaged membrane potential of uninfected INS-1 cells and cells infected with the PIP5K:WT or PIP5K:Δ1-238 virus (n = 5-12) at 12 mM glucose monitored using perforated patch-clamp recording. The error bar is the s.e.m. The resting membrane potential of cells infected with the PIP5K:WT virus is significantly more hyperpolarized than uninfected cells at high glucose. *p < 0.001.
FIG. 5.
Overexpression of PIP5K:WT attenuates insulin secretion response to glucose stimulation. (A) Insulin secretion at 3 mM or 12 mM glucose was measured in uninfected cells, or cells infected with the PIP5K:WT or the PIP5K:Δ1-238 virus. The response is normalized to that observed in uninfected cells at 3 mM glucose. Cells infected with the PIP5K:WT virus had significantly reduced insulin secretion response at 12 mM glucose (3.6 ± 0.4 folds) compared with uninfected cells (9.5 ± 0.6 folds) or cells infected with the PIP5K:Δ1-238 virus (8.4 ± 0.7 folds; n = 5-9 in each case). By contrast, no significant difference was observed between cells infected with the PIP5K:WT virus or uninfected control cells at 3 mM glucose. Note that at 3 mM glucose, cells infected with the PIP5K:Δ1-238 virus showed a 2-fold increase in insulin release; this is likely due to the documented dominant-negative effect of the mutant on WT kinase activity (20; 21), leading to slight decrease in PIP2 levels and elevated basal insulin secretion. *p < 0.001. (B) Membrane capacitance change in response to voltage-clamp depolarizations. The upper trace represents the voltage-clamp protocolused to evoke exocytosis, and the dotted lower traces the capacitance increase observed in PIP5K:WT overexpressing (gray) and uninfected control cells (white). (C) Averaged capacitance increase during the first (left) and all six depolarizations (right) in experiments as in B (n = 8-12; color code as in A). (D) Charge influx during the first depolarization from the same set of cells shown in C. With Cs in the pipette (see Research Design and Methods), the vast majority of the current is through voltage-gated Ca channels (32).
DISCUSSION
Despite the effects of membrane phosphoinositides, especially PIP2, on KATP channel activity having been well documented in vitro studies for some time (11; 12; 33; 34), the relevance of channel regulation by PIP2 to insulin secretion remains controversial (15; 35). To address this issue, it is necessary to directly correlate the interactions between KATP channels and PIP2 in β-cells to insulin secretion. INS-1 clone 832/13 is a rat insulinoma cell line widely used to study β-cell function; it exhibits robust glucose-stimulated insulin secretion, mediated by both KATP-dependent and independent pathways (22). Our studies demonstrate that alterations in KATP channel -PIP2 interactions have profound effects on insulin secretion, establishing a physiological role of PIP2 in controlling insulin secretion through KATP channel regulation.
In altering channel-PIP2 interactions, we took two approaches: one by manipulating the channel subunit Kir6.2, the other by manipulating cellular PIP2 levels. While interpretation of experiments in which Kir6.2 subunit is the subject of manipulation is straightforward, interpretation of experiments involving manipulation of PIP2 concentrations is more complicated due to its role in diverse cellular processes. For example, recent studies indicate that PIP2 is required for recruitment of insulin granules to the release sites during the secondary phase of insulin secretion: a decrease in PIP2 levels reduces, whereas an increase in PIP2 levels enhances insulin secretion (18; 19). In addition, PIP2 has been shown to control the rate of endocytosis (36-38). Curiously, unlike that reported in primary β-cells and chromaffin cells (18; 39), we did not detect a significantly larger increase in membrane capacitance change upon direct voltage-clamp membrane depolarization in INS-1 cells with elevated PIP2 (Fig.5B, C). The discrepancy might be due to differences in the level of PIP2 overexpression; the prolonged high level of PIP2 seen in PIP5K:WT virus infected INS-1 cells might lead to increased membrane endocytosis, masking the capacitance increase expected from enhanced exocytosis. Regardless, even if there is an effect of PIP2 that acts directly on the exocytotic machineary, this effect is likely to be small compare to the effect of PIP2 via KATP channels, as the net result of PIP2 overexpression in our experiments is a decrease in glucose-induced insulin secretion (Fig.5A). Increased endocytosis due to elevated PIP2 might also affect the level of membrane proteins involved in stimulation-secretion coupling, such as KATP channels. If true, this would lead to fewer KATP channels at the cell surface and increased insulin secretion, making our observed impact of enhanced channel-PIP2 interaction on insulin secretion an underestimate. Taken together, despite the multiple mechanisms by which PIP2 may affect insulin secretion, our observation that elevated PIP2 dramatically reduces the ATP sensitivity of endogenous KATP channels (Fig.4) provide strong consistency with a critical role of membrane PIP2 in controlling β-cell KATP channel activity, hence β-cell excitability and insulin secretion.
In conclusion, our study demonstrates that membrane phosphoinositides play an integral role in determining the activity of KATP channels in β-cells. Many hormones, neurotransmitters, and nutrients affect the metabolism of phosphoinositides in β-cells (40-44). Our finding raises the possibility that variation in membrane phosphoinositides under normal and pathological conditions may affect insulin secretion by altering KATP channel activity. Mutations in other Kir channels such as Kir2.1 that impair channel sensitivity to PIP2 have been shown to underlie Anderson syndromes (45). Our study also raises the possibility that naturally occurring mutations in Kir6.2 that alter channel-PIP2 interactions may cause insulin secretion diseases.
ACKNOWLEDGMENTS
We thank Dr. Carol A. Vandenberg for providing the rat Kir6.2 clone, Dr. Christopher Newgard for the 832/13 clone of INS-1 cells, Dr. Peter Rotwein for the GFP-adenovirus, and Dr. J. Nathan Davis for the antiserum against PIP5K. We are grateful to Dr. Wolfhard Almers (Portland, OR; supported by NIH MH60600) for the use of capacitance measurement equipment, and to Drs. Elizabeth Wilson and Zhengfeng Zhou for advice on constructing adenoviruses. This work was supported by National Institutes of Health Grant DK57699 (to S.-L. S.), and the European Foundation for the Study of Diabetes (to S. B.). S.B. was a recipient of an EMBO long-term fellowship during the course of this study.
REFERENCES
- 1.Aguilar-Bryan L, Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev. 1999;20:101–135. doi: 10.1210/edrv.20.2.0361. [DOI] [PubMed] [Google Scholar]
- 2.Ashcroft FM. Adenosine 5′-triphosphate-sensitive potassium channels. Annu Rev Neurosci. 1988;11:97–118. doi: 10.1146/annurev.ne.11.030188.000525. [DOI] [PubMed] [Google Scholar]
- 3.Ashcroft FM, Gribble FM. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia. 1999;42:903–919. doi: 10.1007/s001250051247. [DOI] [PubMed] [Google Scholar]
- 4.Ashcroft FM, Kakei M. ATP-sensitive K+ channels in rat pancreatic beta-cells: modulation by ATP and Mg2+ ions. J Physiol. 1989;416:349–367. doi: 10.1113/jphysiol.1989.sp017765. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Huopio H, Shyng SL, Otonkoski T, Nichols CG. KATP channels and insulin secretion disorders. Am J Physiol Endocrinol Metab. 2002;283:E207–216. doi: 10.1152/ajpendo.00047.2002. [DOI] [PubMed] [Google Scholar]
- 6.Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J, Edghill EL, Frayling TM, Temple IK, Mackay D, Shield JP, Sumnik Z, van Rhijn A, Wales JK, Clark P, Gorman S, Aisenberg J, Ellard S, Njolstad PR, Ashcroft FM, Hattersley AT. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med. 2004;350:1838–1849. doi: 10.1056/NEJMoa032922. [DOI] [PubMed] [Google Scholar]
- 7.Koster JC, Marshall BA, Ensor N, Corbett JA, Nichols CG. Targeted overactivity of β-cell KATP channels induces profound neonatal diabetes. Cell. 2000;100:645–654. doi: 10.1016/s0092-8674(00)80701-1. [DOI] [PubMed] [Google Scholar]
- 8.Aguilar-Bryan L, Bryan J, Nakazaki M. Of mice and men: KATP channels and insulin secretion. Recent Prog Horm Res. 2001;56:47–68. doi: 10.1210/rp.56.1.47. [DOI] [PubMed] [Google Scholar]
- 9.Stanley CA. Hyperinsulinism in infants and children. Pediatr Clin North Am. 1997;44:363–374. doi: 10.1016/s0031-3955(05)70481-8. [DOI] [PubMed] [Google Scholar]
- 10.Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem. 1998;67:481–507. doi: 10.1146/annurev.biochem.67.1.481. [DOI] [PubMed] [Google Scholar]
- 11.Baukrowitz T, Schulte U, Oliver D, Herlitze S, Krauter T, Tucker SJ, Ruppersberg JP, Fakler B. PIP2 and PIP as determinants for ATP inhibition of KATP channels. Science. 1998;282:1141–1144. doi: 10.1126/science.282.5391.1141. [DOI] [PubMed] [Google Scholar]
- 12.Shyng SL, Nichols CG. Membrane phospholipid control of nucleotide sensitivity of KATP channels. Science. 1998;282:1138–1141. doi: 10.1126/science.282.5391.1138. [DOI] [PubMed] [Google Scholar]
- 13.Baukrowitz T, Fakler B. KATP channels gated by intracellular nucleotides and phospholipids. Eur J Biochem. 2000;267:5842–5848. doi: 10.1046/j.1432-1327.2000.01672.x. [DOI] [PubMed] [Google Scholar]
- 14.Ashcroft FM. Exciting times for PIP2. Science. 1998;282:1059–1060. doi: 10.1126/science.282.5391.1059. [DOI] [PubMed] [Google Scholar]
- 15.Tarasov A, Dusonchet J, Ashcroft F. Metabolic regulation of the pancreatic β-cell ATP-sensitive K+ channel: A Pas de Deux. Diabetes. 2004;53(Suppl 3):S113–122. doi: 10.2337/diabetes.53.suppl_3.s113. [DOI] [PubMed] [Google Scholar]
- 16.Hilgemann DW. Getting ready for the decade of the lipids. Annu Rev Physiol. 2003;65:697–700. doi: 10.1146/annurev.physiol.65.092101.142453. [DOI] [PubMed] [Google Scholar]
- 17.De Camilli P, Emr SD, McPherson PS, Novick P. Phosphoinositides as regulators in membrane traffic. Science. 1996;271:1533–1539. doi: 10.1126/science.271.5255.1533. [DOI] [PubMed] [Google Scholar]
- 18.Olsen HL, Hoy M, Zhang W, Bertorello AM, Bokvist K, Capito K, Efanov AM, Meister B, Thams P, Yang SN, Rorsman P, Berggren PO, Gromada J. Phosphatidylinositol 4-kinase serves as a metabolic sensor and regulates priming of secretory granules in pancreatic beta cells. Proc Natl Acad Sci U S A. 2003;100:5187–5192. doi: 10.1073/pnas.0931282100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Lawrence JT, Birnbaum MJ. ADP-ribosylation factor 6 regulates insulin secretion through plasma membrane phosphatidylinositol 4,5-bisphosphate. Proc Natl Acad Sci U S A. 2003;100:13320–13325. doi: 10.1073/pnas.2232129100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Davis JN, Rock CO, Cheng M, Watson JB, Ashmun RA, Kirk H, Kay RJ, Roussel MF. Complementation of growth factor receptor-dependent mitogenic signaling by a truncated type I phosphatidylinositol 4-phosphate 5-kinase. Mol Cell Biol. 1997;17:7398–7406. doi: 10.1128/mcb.17.12.7398. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Shyng SL, Barbieri A, Gumusboga A, Cukras C, Pike L, Davis JN, Stahl PD, Nichols CG. Modulation of nucleotide sensitivity of ATP-sensitive potassium channels by phosphatidylinositol-4-phosphate 5-kinase. Proc Natl Acad Sci U S A. 2000;97:937–941. doi: 10.1073/pnas.97.2.937. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB. Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes. 2000;49:424–430. doi: 10.2337/diabetes.49.3.424. [DOI] [PubMed] [Google Scholar]
- 23.Cartier EA, Conti LR, Vandenberg CA, Shyng SL. Defective trafficking and function of KATP channels caused by a sulfonylurea receptor 1 mutation associated with persistent hyperinsulinemic hypoglycemia of infancy. Proc Natl Acad Sci U S A. 2001;98:2882–2887. doi: 10.1073/pnas.051499698. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Cukras CA, Jeliazkova I, Nichols CG. The role of NH2-terminal positive charges in the activity of inward rectifier KATP channels. J Gen Physiol. 2002;120:437–446. doi: 10.1085/jgp.20028621. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Loussouarn G, Rose T, Nichols CG. Structural basis of inward rectifying potassium channel gating. Trends Cardiovasc Med. 2002;12:253–258. doi: 10.1016/s1050-1738(02)00170-6. [DOI] [PubMed] [Google Scholar]
- 26.Schulze D, Krauter T, Fritzenschaft H, Soom M, Baukrowitz T. Phosphatidylinositol 4,5-bisphosphate (PIP2) modulation of ATP and pH sensitivity in Kir channels. A tale of an active and a silent PIP2 site in the N terminus. J Biol Chem. 2003;278:10500–10505. doi: 10.1074/jbc.M208413200. [DOI] [PubMed] [Google Scholar]
- 27.Shyng SL, Cukras CA, Harwood J, Nichols CG. Structural determinants of PIP2 regulation of inward rectifier KATP channels. J Gen Physiol. 2000;116:599–608. doi: 10.1085/jgp.116.5.599. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Koster JC, Remedi MS, Flagg TP, Johnson JD, Markova KP, Marshall BA, Nichols CG. Hyperinsulinism induced by targeted suppression of beta cell KATP channels. Proc Natl Acad Sci U S A. 2002;99:16992–16997. doi: 10.1073/pnas.012479199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Becker TC, Noel RJ, Coats WS, Gomez-Foix AM, Alam T, Gerard RD, Newgard CB. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 1994;43(Pt A):161–189. doi: 10.1016/s0091-679x(08)60603-2. [DOI] [PubMed] [Google Scholar]
- 30.Krauter T, Ruppersberg JP, Baukrowitz T. Phospholipids as modulators of KATP channels: distinct mechanisms for control of sensitivity to sulphonylureas, K+ channel openers, and ATP. Mol Pharmacol. 2001;59:1086–1093. [PubMed] [Google Scholar]
- 31.Koster JC, Sha Q, Nichols CG. Sulfonylurea and K+-channel opener sensitivity of KATP channels. Functional coupling of Kir6.2 and SUR1 subunits. J Gen Physiol. 1999;114:203–213. doi: 10.1085/jgp.114.2.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Horvath A, Szabadkai G, Varnai P, Aranyi T, Wollheim CB, Spat A, Enyedi P. Voltage dependent calcium channels in adrenal glomerulosa cells and in insulin producing cells. Cell Calcium. 1998;23:33–42. doi: 10.1016/s0143-4160(98)90072-0. [DOI] [PubMed] [Google Scholar]
- 33.Fan Z, Makielski JC. Anionic phospholipids activate ATP-sensitive potassium channels. J Biol Chem. 1997;272:5388–5395. doi: 10.1074/jbc.272.9.5388. [DOI] [PubMed] [Google Scholar]
- 34.Hilgemann DW, Ball R. Regulation of cardiac Na+,Ca2+ exchange and KATP potassium channels by PIP2. Science. 1996;273:956–959. doi: 10.1126/science.273.5277.956. [DOI] [PubMed] [Google Scholar]
- 35.Larsson O, Barker CJ, Berggren PO. Phosphatidylinositol 4,5-bisphosphate and ATP-sensitive potassium channel regulation: a word of caution. Diabetes. 2000;49:1409–1412. doi: 10.2337/diabetes.49.9.1409. [DOI] [PubMed] [Google Scholar]
- 36.Itoh T, Takenawa T. Regulation of endocytosis by phosphatidylinositol 4,5-bisphosphate and ENTH proteins. Curr Top Microbiol Immunol. 2004;282:31–47. doi: 10.1007/978-3-642-18805-3_2. [DOI] [PubMed] [Google Scholar]
- 37.Padron D, Wang YJ, Yamamoto M, Yin H, Roth MG. Phosphatidylinositol phosphate 5-kinase Iβ recruits AP-2 to the plasma membrane and regulates rates of constitutive endocytosis. J Cell Biol. 2003;162:693–701. doi: 10.1083/jcb.200302051. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Wenk MR, Pellegrini L, Klenchin VA, Di Paolo G, Chang S, Daniell L, Arioka M, Martin TF, De Camilli P. PIP kinase Igamma is the major PI(4,5)P2 synthesizing enzyme at the synapse. Neuron. 2001;32:79–88. doi: 10.1016/s0896-6273(01)00456-1. [DOI] [PubMed] [Google Scholar]
- 39.Milosevic I, Sorensen JB, Lang T, Krauss M, Nagy G, Haucke V, Jahn R, Neher E. Plasmalemmal phosphatidylinositol-4,5-bisphosphate level regulates the releasable vesicle pool size in chromaffin cells. J Neurosci. 2005;25:2557–2565. doi: 10.1523/JNEUROSCI.3761-04.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Khan FA, Goforth PB, Zhang M, Satin LS. Insulin activates ATP-sensitive K+ channels in pancreatic β-cells through a phosphatidylinositol 3-kinase-dependent pathway. Diabetes. 2001;50:2192–2198. doi: 10.2337/diabetes.50.10.2192. [DOI] [PubMed] [Google Scholar]
- 41.Iismaa TP, Kerr EA, Wilson JR, Carpenter L, Sims N, Biden TJ. Quantitative and functional characterization of muscarinic receptor subtypes in insulin-secreting cell lines and rat pancreatic islets. Diabetes. 2000;49:392–398. doi: 10.2337/diabetes.49.3.392. [DOI] [PubMed] [Google Scholar]
- 42.Cheng PY, Yasuda H, Katori T, Oka H. Phosphoinositides turnover and insulin secretion in pancreatic islets. Endocrinol Jpn. 1987;34:189–202. doi: 10.1507/endocrj1954.34.189. [DOI] [PubMed] [Google Scholar]
- 43.Doyle ME, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev. 2003;55:105–131. doi: 10.1124/pr.55.1.7. [DOI] [PubMed] [Google Scholar]
- 44.Nunemaker CS, Zhang M, Satin LS. Insulin feedback alters mitochondrial activity through an ATP-sensitive K+ channel-dependent pathway in mouse islets and beta-cells. Diabetes. 2004;53:1765–1772. doi: 10.2337/diabetes.53.7.1765. [DOI] [PubMed] [Google Scholar]
- 45.Lopes CM, Zhang H, Rohacs T, Jin T, Yang J, Logothetis DE. Alterations in conserved Kir Channel-PIP2 interactions underlie channelopathies. Neuron. 2002;34:933–944. doi: 10.1016/s0896-6273(02)00725-0. [DOI] [PubMed] [Google Scholar]

